Five biotech companies that Andrei Doronichev is keeping an eye on

In an interview with Oninvest, businessman and investor Andrei Doronichev named five companies operating at the intersection of biotech, pharmaceuticals, and AI that he is keeping an eye on. One of them—Insilico Medicine—is publicly traded, with its shares listed on the Hong Kong Stock Exchange. The other four are private companies, but all are engaged in cutting-edge research, have a successful track record in the venture capital market, and have received prestigious industry awards.

What kind of companies are these?

A biotechnology company that uses generative AI to identify disease targets, develop drug candidates, and predict clinical trial outcomes. The entire process of creating a candidate molecule for treating a disease is managed by its proprietary Pharma.AI platform.

From the beginning of the year through August 14, its stock rose in price by nearly 20%.

In total, its portfolio includes three dozen drugs at various stages of development. Insilico Medicine’s lead drug, rentosertib, for the treatment of idiopathic pulmonary fibrosis, was developed entirely using AI. In July, the company announced that it had begun the final Phase III clinical trials.

Insilico Medicine was founded in 2014 by Alexander Zhavoronkov, a native of Riga and a former graduate student at Moscow State University. The company is headquartered in Hong Kong and Boston, with offices in Canada, China, and the UAE.

According to Crunchbase, Insilico Medicine raised a total of $624.3 million prior to its IPO. Among its key investors were Prosperity7 (Saudi Aramco’s venture capital fund) and the private equity firm Warburg Pincus.

Insilico Medicine was ranked No. 1 among biotech companies on Fast Company's 2024 list of the most innovative companies and was included in CB Insights' AI 100 list in 2022.

A biotechnology startup that uses generative AI to develop software for protein engineering and programming. Scientists specify the desired protein properties and upload laboratory test results to Cradle’s proprietary platform, which generates new protein sequence variants, predicts their characteristics, and selects the most promising candidates for testing.

It was founded in 2021 in the Netherlands.

According to Crunchbase, Cradle.bio raised €5.5 million from Index Ventures and Kindred Capital in a seed round in 2022. In total, the company has raised nearly $103 million.

In 2025, Bloomberg and Founders Forum Group included Cradle.bio on their list of 25 European startups capable of changing the world.

A biotechnology startup focused on the discovery and development of antibodies against cancerous tumors. The company develops molecules that recognize tumor cells, limit their impact on healthy tissue, activate the immune system, and can serve as the basis for drug development. Its EVA platform selects antibodies suitable for addressing specific problems. Based on specified designs, a robotic laboratory produces different protein variants and then tests their properties.

The company was founded in 2012 in the United Kingdom.

According to Crunchbase, LabGenius has raised a total of $73.2 million over the years. One of its key investors is M Ventures, the venture capital arm of pharmaceutical giant Merck.

A biotechnology startup founded in 2024 in California. It develops fundamental AI models for molecular design. Its goal is to use AI to find a suitable candidate among known molecules or to design a candidate molecule from scratch for a specific biological target. The startup collaborates with pharmaceutical giants Novartis, Pfizer, and Eli Lilly.

According to Crunchbase, Chai Discovery has raised $631 million in the venture capital market in just two years. Its key investors include the hyperscaler Amazon Web Services, OpenAI, and the major venture capital firm General Catalyst.

Chai Discovery has been included in Endpoints 11—an annual list of the most promising biotechnology companies based on 2025 results, compiled by the industry publication Endpoints News. Jiao Zhoran, one of the co-founders of Chai Discovery, received an award from the Chen Institute and the journal Science.

A biotechnology startup that grew out of Google DeepMind's AI lab. Its founder and CEO is Demis Hassabis.

The AlphaFold neural network, developed by DeepMind, has learned to predict the structure of millions of proteins quickly and with high accuracy. For developing an AI model to predict this structure, Hassabis, together with John Jumper—now the former vice president of Google DeepMind— was awarded the 2024 Nobel Prize in Chemistry.

Isomorphic Labs is transforming AlphaFold's technology into a pipeline for developing actual drugs.

The company was founded in 2021. Its headquarters are in London. According to Crunchbase, Isomorphic Labs has raised $2.7 billion in venture capital. Its key investor is the venture capital fund Thrive Capital, founded by Joshua Kushner, the brother of Jared Kushner, son-in-law and advisor to U.S. President Donald Trump.

This article was AI-translated and verified by a human editor